<DOC>
	<DOCNO>NCT00384397</DOCNO>
	<brief_summary>This Phase III , modify single-blind , randomize , parallel-group , multicenter , comparative trial United States design evaluate immunogenicity safety two dos Menactra vaccine administer alone , concomitantly routine pediatric vaccine typically administer 12 15 month age . Primary Objective : To evaluate antibody response meningococcal serogroups A , C , Y , W-135 . Secondary Objectives : Immunogenicity - To evaluate antibody response meningococcal serogroups A , C , Y , W-135 , Menactra vaccine administer alone concomitantly Hib MMRV vaccine . - To evaluate antibody response meningococcal serogroups A , C , Y , W-135 , Menactra vaccine administer alone concomitantly PCV vaccine . Safety - To describe safety profile within 7 30 day vaccination , serious adverse event ( SAEs ) throughout course study .</brief_summary>
	<brief_title>A Study 2 Doses Menactra® , Meningococcal Conjugate Vaccine Healthy Toddlers</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy , determine medical history physical examination . Aged 9 month ( 249 291 day ) time enrollment . The parent legal guardian sign dated Institutional Review Boardapproved inform consent form Serious acute chronic disease ( e.g. , cardiac , renal , metabolic , rheumatologic , psychiatric , hematologic , autoimmune disorder , diabetes , atopic condition , congenital defect , convulsion , encephalopathy , blood dyscrasia , leukemia , lymphomas type , malignant neoplasm affect bone marrow lymphatic system , acute untreated tuberculosis ) could interfere trial conduct completion . Known suspected impairment immunologic function . Acute medical illness within last 72 hour , temperature ≥ 100.4 ºF ( ≥ 38.0 ºC ) time enrollment . History document invasive meningococcal disease previous meningococcal vaccination . Known human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C seropositivity report parent legal guardian Received either immune globulin blood product within last 3 month , receive injected oral corticosteroid , immunomodulator therapy within 6 week study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day individual ( e.g. , asthmatic ) short schedule oral steroid last 3 4 day may include trial long receive one course within last two week prior enrollment . Topical steroid include exclusion criterion . Anticipated receive oral inject antibiotic therapy within 72 hour prior study blood draw . Topical antibiotic antibiotic drop include exclusion criterion . Suspected known hypersensitivity vaccine component , history lifethreatening reaction study vaccine vaccine contain substance . For ProQuad vaccine recipient , include hypersensitivity gelatin history anaphylactic reaction neomycin . Thrombocytopenia bleed disorder contraindicate intramuscular ( IM ) vaccination . Parent legal guardian unable unwilling comply study procedure . Participation another interventional clinical trial 30 day precede enrollment , participation another clinical trial involve investigation drug , vaccine , medical procedure , medical device subject 's trial period . Diagnosed condition , opinion investigator , would pose health risk subject interfere evaluation vaccine . Received vaccine 30day period prior receipt study vaccine , schedule receive vaccination influenza vaccination hyposensitization therapy 30day period receipt study vaccine . Hyposensitization therapy influenza vaccination may receive two week two week receive study vaccine . Subjects receive 4th dose Pneumococcal Conjugate ( PCV ) Hib vaccine first dose MeaslesMumpsRubellaVaricella ( MMRV ) vaccine enrollment . Personal family history GuillainBarré Syndrome ( GBS ) . History seizure , include febrile seizure , neurologic disorder . Known hypersensitivity dry natural rubber latex ( pertinent Menactra® vaccine needle shield )</criteria>
	<gender>All</gender>
	<minimum_age>249 Days</minimum_age>
	<maximum_age>305 Days</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Menactra vaccine</keyword>
	<keyword>Meningococcal meningitis</keyword>
	<keyword>Measles</keyword>
	<keyword>Mumps</keyword>
	<keyword>Rubella</keyword>
	<keyword>Varicella virus</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
	<keyword>Pneumococcal conjugate vaccine</keyword>
</DOC>